Literature DB >> 11057810

Vasopressin-mediated adrenocorticotropin release increases plasma cortisol concentrations during cardiopulmonary resuscitation.

E Kornberger1, A W Prengel, A Krismer, B Schwarz, V Wenzel, K H Lindner, P Mair.   

Abstract

OBJECTIVE: Vasopressin is a possible stimulus for both adrenocorticotropin (ACTH) and endothelin-1 release. The aim of this study was to compare plasma concentrations of ACTH, cortisol, and endothelin-1 after epinephrine or vasopressin administration in an experimental animal model of cardiopulmonary resuscitation (CPR).
DESIGN: Prospective, randomized, controlled animal study.
SETTING: A university research laboratory.
SUBJECTS: Fourteen 12- to 14-wk-old domestic pigs.
INTERVENTIONS: After 4 mins of cardiac arrest and 3 mins of external chest compression, the pigs were randomly assigned to receive either 0.045 mg/kg epinephrine (n = 7) or 0.4 units/kg vasopressin (n = 7). At 5 mins after drug administration, defibrillation was attempted.
MEASUREMENTS AND MAIN RESULTS: Coronary perfusion pressure, ACTH, cortisol, and endothelin-1 were measured before cardiocirculatory arrest, during CPR before drug administration, and at 90 secs and 5 mins after drug administration. Coronary perfusion pressure was comparable between groups. All seven animals in the vasopressin group survived, but only one pig in the epinephrine group survived (p = .005). ACTH and cortisol concentrations remained unchanged in epinephrine-treated animals, but increased significantly after vasopressin administration and were significantly higher than in epinephrine-treated animals 5 mins after drug administration. Endothelin-1 concentrations remained unchanged during the study period and were comparable between both groups.
CONCLUSIONS: Vasopressin is a potent stimulus for ACTH secretion, but does not trigger endothelin-1 release from vascular cells during cardiac arrest and CPR. The increased plasma cortisol concentrations caused by the enhanced ACTH release after vasopressin may be one factor contributing to the improved outcome repeatedly observed with vasopressin in animal models of CPR.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11057810     DOI: 10.1097/00003246-200010000-00028

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  7 in total

1.  Prognostic value of relative adrenal insufficiency after out-of-hospital cardiac arrest.

Authors:  Frédéric Pene; Hervé Hyvernat; Vincent Mallet; Alain Cariou; Pierre Carli; Christian Spaulding; Marie-Annick Dugue; Jean-Paul Mira
Journal:  Intensive Care Med       Date:  2005-04-19       Impact factor: 17.440

Review 2.  Current Challenges in Neonatal Resuscitation: What is the Role of Adrenaline?

Authors:  Roberto Antonucci; Luca Antonucci; Cristian Locci; Annalisa Porcella; Laura Cuzzolin
Journal:  Paediatr Drugs       Date:  2018-10       Impact factor: 3.022

Review 3.  Management of vasodilatory shock: defining the role of arginine vasopressin.

Authors:  Martin W Dunser; Volker Wenzel; Andreas J Mayr; Walter R Hasibeder
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 4.  Drug administration in animal studies of cardiac arrest does not reflect human clinical experience.

Authors:  Joshua C Reynolds; Jon C Rittenberger; James J Menegazzi
Journal:  Resuscitation       Date:  2007-03-13       Impact factor: 5.262

Review 5.  Glucocorticoids as an emerging pharmacologic agent for cardiopulmonary resuscitation.

Authors:  Giolanda Varvarousi; Antonia Stefaniotou; Dimitrios Varvaroussis; Theodoros Xanthos
Journal:  Cardiovasc Drugs Ther       Date:  2014-10       Impact factor: 3.727

6.  Steroid use after cardiac arrest is associated with favourable outcomes: a systematic review and meta-analysis.

Authors:  Bo Liu; Qiang Zhang; Chunsheng Li
Journal:  J Int Med Res       Date:  2020-05       Impact factor: 1.671

7.  Efficacy of combination triple therapy with vasopressin, steroid, and epinephrine in cardiac arrest: a systematic review and meta-analysis of randomized-controlled trials.

Authors:  Fatemeh Saghafi; Negar Bagheri; Amin Salehi-Abargouei; Adeleh Sahebnasagh
Journal:  J Intensive Care       Date:  2022-02-02
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.